Imperial College London
Alternate

Emeritus ProfessorKimFox

Faculty of Medicine, National Heart & Lung Institute

Emeritus Professor
 
 
 
//

Contact

 

+44 (0)20 7594 7966kim.fox

 
 
//

Assistant

 

Ms Deborah Curcher +44 (0)20 7594 7966

 
//

Location

 

Guy Scadding BuildingRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Picard:2019:10.1016/j.jacc.2019.01.016,
author = {Picard, F and Bhatt, DL and Ducrocq, G and Elbez, Y and Ferrari, R and Ford, I and Tardif, J-C and Tendera, M and Fox, KM and Steg, PG},
doi = {10.1016/j.jacc.2019.01.016},
journal = {JACC - Journal of the American College of Cardiology},
pages = {1362--1364},
title = {Gerneralizability of the REDUCE-IT trial in patients with stable coronary artery disease},
url = {http://dx.doi.org/10.1016/j.jacc.2019.01.016},
volume = {73},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Epidemiological studies suggest that both moderate and severe hypertriglyceridemia are associated with increased long term cardiovascular risk and mortality. Interestingly, the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention (REDUCE-IT) randomized trial recently enrolled 8179 statin-treated patients with elevated triglycerides levels (135mg/dL and <500mg/dL) and either established cardiovascular disease or diabetes plus at least one risk factor, and demonstrated that high dose (4 g/day) of icosapent ethyl reduced the risk of ischemic events, including cardiovascular death (1). Indeed, the secondary prevention cohort represented 70.7% of the total cohort, which experienced a lower rate of the key secondary efficacy composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke as compared to the placebo group (12.5% vs 16.9% HR:0.72, 95%CI (0.63-0.82).
AU  - Picard,F
AU  - Bhatt,DL
AU  - Ducrocq,G
AU  - Elbez,Y
AU  - Ferrari,R
AU  - Ford,I
AU  - Tardif,J-C
AU  - Tendera,M
AU  - Fox,KM
AU  - Steg,PG
DO  - 10.1016/j.jacc.2019.01.016
EP  - 1364
PY  - 2019///
SN  - 0735-1097
SP  - 1362
TI  - Gerneralizability of the REDUCE-IT trial in patients with stable coronary artery disease
T2  - JACC - Journal of the American College of Cardiology
UR  - http://dx.doi.org/10.1016/j.jacc.2019.01.016
UR  - http://hdl.handle.net/10044/1/68198
VL  - 73
ER  -
Download